IGI Logo

Aurobindo Pharma is currently trading at Rs. 520.70, up by 4.35 points or 0.84% from its previous closing of Rs. 516.35 on the BSE.

The scrip opened at Rs. 518.00 and has touched a high and low of Rs. 524.60 and Rs. 512.25 respectively. So far 75491 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1017.15 on 14-Jun-2021 and a 52 week low of Rs. 511.80 on 07-Jun-2022.

Last one week high and low of the scrip stood at Rs. 546.50 and Rs. 511.80 respectively. The current market cap of the company is Rs. 30586.00 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.30% and 9.86% respectively.

Aurobindo Pharma’s wholly owned subsidiary company -- Eugia Pharma Specialties has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Leuprolide Acetate Injection, 14 mg/2.8 mL MDV (Kit). Leuprolide Acetate Injection, 14 mg/2.8 mL (1 mg/0.2 mL), Multiple-Dose Vials, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lupron Injection, 14 mg/2.8 mL (1 mg/0.2 mL), of AbbVie Endocrinology Inc. (AbbVie). The product is being launched this month. The approved product has an estimated market size of $83 million for the twelve months ending April 2022, according to IQVIA.

This is the 140th ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products. Leuprolide Acetate for injection is indicated for the treatment used to treat the symptoms associated with advanced prostate cancer by way of Palliative treatment of advanced prostatic cancer.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.